Introduction
Chemokine receptor CXCR4 and one of its two ligands, CXCL12 (also known as stromal cell derived factor 1 [SDF-1]), are involved in the migration, homing, mobilization, and survival of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) (1). The genetic disorder WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome manifests as a primary immunodeficiency and involves an autosomal dominant gainof-function CXCR4 mutation. In this issue, Gao et al.
(2) provide a follow-up on previous studies that have advanced the understanding of the pathophysiology and treatment of WHIM and a role for CXCR4 in the disease. Allogeneic BM transplantation has been used to cure several patients with WHIM (3, 4), and an antagonist of CXCR4 (5), originally called AMD3100 and more recently termed plerixafor (Mozobil, Sanofi), is currently being evaluated in a clinical trial for this disorder (6-8). In their previous study, McDermott et al. reported on one patient with WHIM in whom chromothripsis (known as chromosome shattering) resulted in spontaneous deletion of the WHIM allele in a single HSC and subsequent cure of WHIM syndrome in the individual (9) . While 164 genes were deleted by this chromothriptic event, Gao et al. have now focused on CXCR4 and found a selective growth advantage of Cxcr4-haploinsufficient (Cxcr4 +/o ) mouse BM HSCs that yielded almost total chimerism of myeloid cells in a congenic mouse competitive transplant setting (2). Cxcr4 +/o BM cells resulted in stable longterm engraftment beyond that of BM from either WHIM model mice (Cxcr4 +/w ) or WT Cxcr4 +/+ animals in the setting of competitive transplantation following lethal irradiation of congenic mouse recipients. Moreover, recipient Cxcr4 +/w WHIM mice were able to accept the engraftment of Cxcr4 +/o HSCs without any conditioning, and a small percentage of donor Cxcr4 +/o HSCs were able to support more than 70% long-term chimerism of myeloid cells in unconditioned Cxcr4 +/w mice, resulting in correction of the blood myeloid deficiency in Cxcr4 +/w WHIM mice ( Figure 1A ).
Based on these data, Gao et al. suggested future gene editing possibilities to delete the WHIM allele in donor cells for curative autologous transplantation that would not require conditioning of the patient. In fact, the actual implications of these studies may go well beyond selective correction of the clinical WHIM syndrome, as engraftment involves the homing characteristics of donor cells and the nurturing capacity of the BM microenvironment. Additional translational aspects of the improved engraftment of Cxcr4haplosufficient HSCs that extend beyond WHIM ( Figure 1B ) are discussed below.
Role of CXCR4
Cord blood (CB) hematopoietic cell transplantation (HCT) is a viable alternative source of HLA-and partially HLAmatched donor cells for treatment of malignant and nonmalignant genetic diseases, with over 40,000 CB HCTs done to date (10) . A continuing disadvantage of CB HCT is the length of time it takes for recovery of donor neutrophils, platelets, and immune cells, as compared with BM or mobilized peripheral blood HCT. Attempts to enhance engraftment of CB for more efficient HCT have included ex vivo expansion of HSCs and HPCs and/ or enhancing the homing efficiency of HSCs (11) . Although Gao et al.
(2) did not demonstrate that loss of one Cxcr4 allele in Cxcr4 +/o mice enhances the speed of engraftment in their mouse models, the demonstration that decreasing, without complete loss of, CXCR4 expression on donor cells may enhance homing and engraftment may be a lesson to incorporate for improving CB HCT. It may seem counterintuitive to decrease CXCR4 expression of donor cells for enhanced engraftment, as CXCR4 is implicated in survival and homing of HSCs and HPCs (1). However, CXCR4 is not necessarily of absolute importance itself in these functions, as expression levels of CXCR4 do not always correlate with engraftment efficiency. Collection of mouse BM or human CB under hypoxic conditions results in increased numbers of functionally engrafting HSCs, yet these cells exhibit significant decreases in CXCR4 expres- WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a genetic autoimmune disorder that results from gain-offunction mutations in the gene encoding chemokine receptor CXCR4. A previous study characterized a patient with WHIM who underwent a chromothriptic event that resulted in spontaneous deletion of the WHIM allele in a single hematopoietic stem cell and subsequent cure of the disease. In this issue of the JCI, Gao et al. extend this work and show that Cxcl4-haplosufficient bone marrow has a selective advantage for long-term engraftment in murine WHIM models. Moreover, successful engraftment occurred without prior conditioning of recipients. Together, these results have important implications for improving hematopoietic stem/progenitor cell transplant not only for patients with WHIM but also for all patients who may require the procedure. 
Role of hypoxia collection
A recent study that evaluated collection and processing of BM and CB cells in an hypoxic environment of about 3% oxygen has potential relevance for the engraftment of genetically modified WHIM and other patient donor HSCs and/or HPCs (12) . Hypoxic collection and processing of cells yields increased numbers of phenotypically defined and engrafting HSCs compared with those collected in ambient air conditions (12) . In ambient air, the phenomenon of extra physiologic oxygen shock/stress (EPHOSS) causes rapid differentiation of HSCs through a mitochondrial permeability transition pore/p53/ cyclophilin D axis and subsequent release of ROS (12) . Collection and processing of cells in hypoxia is cumbersome and not easily adapted for routine clinical use; however, EPHOSS can be counteracted in ambient air with cyclosporine A (12) or by combinations of antioxidants and/or epigenetic enzyme inhibitors (17) . None of these measures to counteract EPHOSS during ambient air collection of cells have yet to be adapted for clinical utility, though sion (12) . There are likely many receptors involved in HSC homing that may function alone or in concert with CXCR4.
Role of DPP4 and CXCL12
A component not critically addressed by Gao et al. is the CXCR4 ligand CXCL12, which is one of a number of proteins that have a truncation site for the enzyme dipeptidylpeptidase 4 (DPP4, also known as CD26) (13, 14) . DPP4 is present on the surface of HSCs, HPCs, and other cells, and is found within cells and in serum (14, 15) . DPP4 removes two amino acids from the N-terminus of proteins, usually when the second amino acid is a proline or alanine (13, 14) . Truncation of CXCL12 by DPP4 results in decreased chemotaxis, homing, and engraftment of HSCs and HPCs (15, 16 ); yet, little has been done to determine what the ratio and functional implications of full-length versus DPP4truncated CXCL12, or other proteins, are in mice and humans. A role for DPP4truncated molecules has been inferred in studies using DPP4-induced truncation of selective cytokines and chemokines and/or DPP4 inhibitors (e.g., diprotin A, a tri-peptide; ILE-PRO-ILE; or the orally active small-molecule sitagliptin [Januvia], which is used to treat type 2 diabetes) or Cd26 -/cells and mice (15, 16) . Unfortunately, there are no antibodies available to distinguish between DPP4truncated and full-length proteins. The production and use of such antibodies 
